

Dear Ms Cen,

31 October 2017

Angy (China) Medical Limited (the "Company") – Periodic Disclosure Query

We refer to the Interim Financial Report lodged on 20th October 2017 on which NSX has made below observations.

1. Revenue reported for the period ended 30 June 2017 is HKD49,036,746, which is substantially higher compared to HKD28,545,337 for the period ended 30 June 2016.

The financial statements do not have supporting notes for the material change in the revenue.

NSX also notes that no announcements have been made by the Company highlighting the significant change in the revenue for the period before the reporting date.

2. In relation to the above observations please respond to the below questions.
 - a) Can the Company please provide information supporting the material change in its revenue?
 - b) When did the Company first become aware of the information regarding possible change in business activities that could result in material change in revenue?
 - c) Does the Company believe it is in compliance with Listing Rule 6.4 as the financial position of the group has significantly changed from the period ended 30 June 2016 to the period ended 30 June 2017 without any information being released to the market supporting the significant change in the financial position?

Please be reminded that the Issuer must comply with Chapter 6CA of the Corporations Act and Listing Rules Section IIA 6.4, 6.5 and 6.5A under continuous disclosure.

Your response should be provided to me directly via email no later than 4pm on 6th November 2017. Your response will be released to the market along with a copy of this letter. If you wish to discuss the content of your response, please do not hesitate to contact me as soon as possible.

Listing Rule 6.4

The NSX continuous disclosure rule states:

Generally, and apart from compliance with all the specific requirements, the issuer shall keep the Exchange informed without delay, for dissemination of any information relating to the group of which it is aware that:

- is necessary to enable the Exchange and the public to appraise the financial position of the issuer and the group;
- is necessary to avoid the establishment of a false market in its securities; or
- a reasonable person would expect to have a material effect on the price or value of its securities.

Such information must be made available to the Exchange before the time at which any other public announcement of the information is made.

These provisions will be breached by an issuer who intentionally, recklessly or negligently fails to notify the Exchange of information that:

- is not generally available; and
- a reasonable person would expect, if it were generally available, to have a material effect on the price or value of its securities.

Yours sincerely

Ingrid Wei
Market Surveillance Analyst

Ms. Weiting Cen
Company Secretary
Angy (China) Medical Limited
Unit 2303 23/F, New World Tower 1
18 Queen's Road
Central Hong Kong